Azitra Inc
azitrainc.comWhat Do They Do?
Develops engineered bacteria and proteins for treatments of skin diseases.
10-K for FY2025, filed Feb 27, 2026We are an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using…View ↗
ATR-12, a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and sometimes fatal…View ↗
Our protein delivery capability for treating skin conditions is based on engineering S. epidermidis and other microbes to secrete proteins…View ↗
Who Are Their Customers?
A research partner pays for joint development work; federal agencies and nonprofit research institutions provide research grants. Azitra has not established a commercial sales or distribution organization.
10-K for FY2025, filed Feb 27, 2026The Company generates service revenue through a joint development agreement with a research partner. The Company recognizes revenue related…View ↗
The Company also generates grant revenue, which represents monies received on contracts with various federal agencies and nonprofit…View ↗
Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We plan to build…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$3.3MView ↗
- ▲ +16% (Loss)
- vs −$2.9M in Q2 FY2025
Who Do They Compete With?
Competes with Sixera Pharma, Quoin Pharmaceuticals, Boehringer Ingelheim, Daiichi Sankyo, ResVita Bio, MatriSys, Hoth Therapeutics, Lutris Pharma, and Daewoong Pharmaceutical
10-K for FY2025, filed Feb 27, 2026We are also aware that Sixera Pharma initiated a clinical trial in Europe with SXR-1096, a topical small molecule KLK inhibitor in December…View ↗
Loading...
